Gurnet Point-backed Boston Pharmaceuticals supercharges pipeline with twin deals grabbing top cast-offs from GSK, Novartis
The executive crew at Boston Pharmaceuticals has been busy.
In one 48-hour stretch they completed two big in-licensing deals with a pair of the world …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
